Smallpox Monoclonal Antibody
Treatment of smallpox disease complications
Phase 1Active
Key Facts
Indication
Treatment of smallpox disease complications
Phase
Phase 1
Status
Active
Company
About Emergent BioSolutions
Emergent BioSolutions is a publicly traded biopharmaceutical company specializing in medical countermeasures against public health threats, including chemical, biological, radiological, and nuclear (CBRN) agents, as well as emerging infectious diseases. The company operates through a fully integrated model encompassing development, manufacturing, and commercialization. Its portfolio includes FDA-approved products for anthrax, smallpox, botulism, and opioid overdose, positioning it as a critical partner to governments worldwide. Emergent's strategic focus is on preparedness and rapid response capabilities for health security emergencies.
View full company profile